drugset / Trial / NCT00165464
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Phase 2
Completed
54 enrolled
Dana-Farber Cancer Institute
Aventis Pharmaceuticals · collabBeth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabMassachusetts General Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.
Timeline
- Start
- 2001-08
- Primary completion
- 2005-03
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 50 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 65 mg/m2 | — |